Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Pathology, The Kyorin University School of Medicine, Tokyo, Japan.
Histopathology. 2021 Jun;78(7):943-950. doi: 10.1111/his.14307. Epub 2021 Mar 26.
En-bloc transurethral resection (TUR) of bladder tumour (ERBT) is designed to provide more accurate pathological diagnosis of specimens than conventional TUR of bladder tumour (cTURBT). Some studies have reported that T1 bladder cancer substage could be a prognostic factor in assessing tumour progression, but such substaging has not been widely adopted because of problems with pathological diagnosis using cTURBT specimens. The aim of this study was to evaluate the possible advantages of en-bloc TUR specimens in T1 substaging following assessment by a panel of 10 pathologists.
We assessed the substages in 123 patients (cTURBT, n = 91; ERBT, n = 32) who were diagnosed with pT1 bladder cancer. We randomly selected 10 ERBT specimens and 10 cTURBT specimens with cancer invasion areas equivalent to those of their corresponding ERBT specimens. Ten pathologists performed pT1 substaging for pT1a/b/c and pT1m/e in 20 patients (cTURBT, n = 10; ERBT, n = 10). We evaluated diagnostic times and rates of diagnostic concordance among these pathologists, comparing cTURBT and ERBT. The median diagnostic times per slide were 87.7 s [interquartile range (IQR) 71.9-109.2 s) for cTURBT and 54.7 s (IQR 46.0-59.6 s) for ERBT (P = 0.009). The rate of diagnostic concordance was significantly better for ERBT specimens. For pT1a/b/c, the median concordance rates were 50% for cTURBT and 80% for ERBT (P = 0.02); for pT1m/e, the median concordance rates were 70% for cTURBT and 90% for ERBT (P = 0.05). For pT1a/b/c, the average κ-values between the pathologist and the standard diagnosis were 0.04 for cTURBT and 0.47 for ERBT.
The use of ERBT specimens shortened the diagnostic time and minimised interobserver variability for T1 substaging compared with the use of cTURBT specimens.
整块经尿道膀胱肿瘤切除术(ERBT)旨在提供比传统经尿道膀胱肿瘤切除术(cTURBT)更准确的肿瘤标本病理诊断。一些研究报告称 T1 膀胱癌亚分期可作为评估肿瘤进展的预后因素,但由于 cTURBT 标本的病理诊断存在问题,该亚分期尚未得到广泛应用。本研究旨在评估 10 位病理学家评估的整块 TUR 标本在 T1 亚分期中的可能优势。
我们评估了 123 例诊断为 pT1 膀胱癌患者(cTURBT,n=91;ERBT,n=32)的亚分期。我们随机选择了 10 例 ERBT 标本和 10 例肿瘤侵袭面积与相应 ERBT 标本相当的 cTURBT 标本。10 位病理学家对 20 例患者(cTURBT,n=10;ERBT,n=10)的 pT1a/b/c 和 pT1m/e 进行了 pT1 亚分期。我们评估了这些病理学家对 cTURBT 和 ERBT 的诊断时间和诊断一致性率,并进行了比较。每例患者每例患者的平均诊断时间为 87.7 秒[四分位距(IQR)71.9-109.2 秒],ERBT 为 54.7 秒(IQR 46.0-59.6 秒)(P=0.009)。ERBT 标本的诊断一致性率明显更好。对于 pT1a/b/c,cTURBT 的中位一致性率为 50%,ERBT 为 80%(P=0.02);对于 pT1m/e,cTURBT 的中位一致性率为 70%,ERBT 为 90%(P=0.05)。对于 pT1a/b/c,病理学家与标准诊断之间的平均κ 值为 cTURBT 0.04,ERBT 0.47。
与使用 cTURBT 标本相比,ERBT 标本缩短了 T1 亚分期的诊断时间,减少了观察者间的变异性。